Tonapofylline
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319815

CAS#: 340021-17-2

Description: Tonapofylline, also known as BG9928, is a selective adenosine-1 receptor antagonist under development for the treatment of heart failure. Tonapofylline promotes natriuresis and diuresis, and may preserve glomerular filtration rate in patients with heart failure. Additionally, pilot data indicate that tonapofylline may be renoprotective in the setting of concomitant treatment with a loop-diuretic. Tonapofylline has natriuretic effects and is able to maintain renal function, which can be beneficial to patients with congestive heart failure.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 120 Same day
10mg USD 190 Same day
25mg USD 350 Same day
50mg USD 550 Same day
100mg USD 950 Same day
200mg USD 1650 Same day
500mg USD 2450 Same day
1g USD 3250 Same day
2g USD 5650 Same day
Inquire bulk and customized quantity

Pricing updated 2020-10-28. Prices are subject to change without notice.

Tonapofylline, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319815
Name: Tonapofylline
CAS#: 340021-17-2
Chemical Formula: C22H32N4O4
Exact Mass: 416.2424
Molecular Weight: 416.522
Elemental Analysis: C, 63.44; H, 7.74; N, 13.45; O, 15.36


Synonym: BG9928; BG-9928; BG 9928; Tonapofylline.

IUPAC/Chemical Name: 3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)bicyclo[2.2.2]octan-1-yl)propanoic acid

InChi Key: ZWTVVWUOTJRXKM-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)

SMILES Code: O=C(O)CCC1(CC2)CCC2(C(N3)=NC(N(CCC)C(N4CCC)=O)=C3C4=O)CC1


Technical Data

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Li Z, Tenhoor C, Marbury T, Swan S, Zhu Y, Ticho B. Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects. Int J Clin Pharmacol Ther. 2011 Sep;49(9):563-70. PubMed PMID: 21888869.

2: Li Z, Gan LS, Marbury T, Lasseter KC, Natarajan A, Stecher S, Wei D, Yang L, Freedman D, Deykin A. Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment. J Clin Pharmacol. 2012 Apr;52(4):543-51. doi: 10.1177/0091270011400413. Epub 2011 May 24. PubMed PMID: 21610206.

3: Gottlieb SS, Ticho B, Deykin A, Abraham WT, Denofrio D, Russell SD, Chapman D, Smith W, Goldman S, Thomas I. Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol. 2011 Jun;51(6):899-907. doi: 10.1177/0091270010375957. Epub 2010 Oct 6. PubMed PMID: 20926754.

4: Li Z, TenHoor C, Marbury T, Swan S, Ticho B, Rogge M, Nestorov I. Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. J Clin Pharmacol. 2011 Jul;51(7):1004-14. doi: 10.1177/0091270010377633. Epub 2010 Oct 6. PubMed PMID: 20926751.

5: Ensor CR, Russell SD. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010 Oct;11(14):2405-15. doi: 10.1517/14656566.2010.514605. Review. PubMed PMID: 20807184.

6: Gill A, Wortham K, Costa D, Davis W, Ticho B, Whalley E. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol. 2009;30(6):521-6. doi: 10.1159/000248762. Epub 2009 Oct 13. PubMed PMID: 19828940.

7: Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol. 2009;(193):25-58. doi: 10.1007/978-3-540-89615-9_2. Review. PubMed PMID: 19639278.

8: Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther. 2008 Winter;26(4):276-86. doi: 10.1111/j.1755-5922.2008.00059.x. Review. PubMed PMID: 19035879.

9: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098.

10: Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, Zhu Y, Ticho B, Abraham WT. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol. 2007 Aug 14;50(7):600-6. Epub 2007 Jul 30. PubMed PMID: 17692744.

11: Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A, Kim J, Sullivan G, Linden J. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. PubMed PMID: 17125264.

12: Doggrell SA. BG-9928 (Biogen Idec). Curr Opin Investig Drugs. 2005 Sep;6(9):962-8. PubMed PMID: 16187697.

13: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review. PubMed PMID: 14988742.

14: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.

15: Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther. 2004 Mar;308(3):846-56. Epub 2003 Nov 21. PubMed PMID: 14634049.